AGO1 (Argonaute RISC Component 1) Gene: Structure, Function, and Clinical Significance

A comprehensive biomedical resource on AGO1, a key regulator of microRNA-mediated gene silencing, including genomic data, expression profiles, disease associations, and mutation landscape.

Gene Information Card

Symbol AGO1
Full Name Argonaute RISC Component 1
Gene Type Protein coding
Chromosomal Location 1p34.3
NCBI Gene ID 26523 ncbi.nlm.nih.gov/gene/26523
Ensembl ID ENSG00000192870
UniProt ID Q9UL18
OMIM ID 606228
HGNC ID HGNC:3262
Aliases EIF2C1, hAgo1, MGC102730

Description

AGO1 encodes a member of the Argonaute protein family, which are essential components of the RNA-induced silencing complex (RISC). AGO1 binds to microRNAs (miRNAs) and small interfering RNAs (siRNAs) to mediate post-transcriptional gene silencing through mRNA cleavage or translational repression. It plays critical roles in development, cell differentiation, and stress responses. AGO1 is also involved in chromatin remodeling and DNA repair. Dysregulation of AGO1 has been implicated in various cancers and neurodevelopmental disorders.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Cancer (multiple types) Altered AGO1 expression affects miRNA processing and gene silencing, promoting oncogenesis or tumor suppression depending on context. COSMIC; PubMed studies
Neurodevelopmental disorders AGO1 mutations may disrupt miRNA-mediated regulation of neuronal genes, contributing to intellectual disability or autism. ClinVar; OMIM
Viral infections AGO1 interacts with viral miRNAs or siRNAs, influencing host antiviral defense. UniProt; PubMed

Expression Profile

Tissue Expression
Tissue nTPM level
Brain High High
Testis High High
Ovary Medium Medium
Lung Medium Medium
Liver Low Low
Cell Line Expression
Cell Line nTPM Notes
HEK293 High Commonly used for functional studies
HeLa Medium Cervical cancer cell line
MCF7 Medium Breast cancer cell line
HepG2 Low Hepatocellular carcinoma
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1340A>G (p.Asp447Gly) Missense Rare Potential impact on miRNA binding; observed in cancer samples
c.2345C>T (p.Thr782Met) Missense Rare Reported in neurodevelopmental disorder cases
c.1234delA (p.Arg412fs) Frameshift Very rare Loss-of-function; associated with altered gene silencing
Mutation functional classification

Loss of Function (LOF)

Frameshift or nonsense mutations that truncate the protein, impairing RISC assembly and miRNA-mediated silencing.

Gain of Function (GOF)

Missense mutations that enhance AGO1 stability or binding affinity, potentially leading to excessive gene silencing.

Dominant Negative (DN)

Mutations that disrupt the interaction with other RISC components, interfering with wild-type AGO1 function.

Gene Ontology (GO)

• RNA binding • mRNA binding
• endonuclease activity • protein binding
• nucleic acid binding • cytoplasm
• P-body • RISC complex
• regulation of gene expression • RNA interference

Pathways

• MicroRNA biogenesis and function
• RNA interference (RNAi)
• Gene silencing
• Post-transcriptional regulation

Protein Summary

AGO1 is a ~97 kDa protein that contains PAZ and PIWI domains. The PAZ domain binds to the 3' end of small RNAs, while the PIWI domain provides endonucleolytic activity for mRNA cleavage. AGO1 interacts with Dicer, TRBP, and other RISC components to facilitate target recognition and silencing. It is ubiquitously expressed but enriched in brain and reproductive tissues. Post-translational modifications, such as phosphorylation, regulate its activity and stability.

Related Products

Product name Cat.No. Species Gene ID
AGO1 Knockout HeLa Cell Line EDJ-KQ22672 Human 26523 Details Get a Quote
AGO1 Knockout HCT 116 Cell Line EDJ-KQ22671 Human 26523 Details Get a Quote
AGO1 Knockout A-549 Cell Line EDJ-KQ22670 Human 26523 Details Get a Quote
AGO1 Knockout HEK293 Cell Line EDJ-KQ2301 Human 26523 Details Get a Quote

Biological Process

Gene Expression and Regulation: A Complete Technical Map from Mechanism to Validated Cell Models

Promoters, Enhancers and 3D Genome Organization: How to Validate Regulatory Relationships with Editing and Interference Tools

Enhancer–Gene Pair Validation: A Complete Technical Roadmap from Candidate Element to Publishable Evidence

CRISPR Deletion vs CRISPRi for Regulatory Elements: Choosing by Evidence Requirement

Building Reporter Cell Lines for Quantitative Regulatory Readouts

TAD Boundaries and Insulators: What They Constrain and What They Do Not Prove

Super-Enhancers and Cell Identity: Design Strategies for Functional Validation

Validating Transcription Factor Binding Sites: From ChIP Peaks to Functional Evidence

From GWAS Signal to Causal Variant: Functional Validation of Non-Coding Risk Loci

Enhancer Redundancy and Shadow Enhancers: Designing Controls That Catch Compensation

Core Promoter Elements: Dissecting Initiator, TATA and CpG-Island Promoters

Single-Cell Multi-Omics for Mapping Regulatory Elements in Heterogeneous Tissues

How Many Candidate Enhancers Can a Single CRISPRi Screen Test?

What Fragment Size Should Be Deleted When Removing an Enhancer?

How to Design sgRNAs for Enhancer Deletion

What Effect Size Counts as Biologically Meaningful in Enhancer Studies?

What Controls Are Required for a Regulatory Element Knockout?

How to Confirm a TAD Boundary Is Functional

Can ATAC-seq Alone Identify Functional Enhancers?

What Is a Shadow Enhancer, and Why Does It Break Your Screen?

How to Report Negative Results in Regulatory Element Studies

Distance Window or TAD Boundary: Which Constraint Matters More?

DNA Methylation, Histone Marks and Chromatin State: Selecting and Validating Epigenome-Editing Tools

CRISPRoff, dCas9-TET and dCas9-p300: A Practical Comparison for Targeted Epigenetic Editing

How Long Does Epigenetic Silencing Last? Stability, Inheritance and Reversibility

DNMT and TET Knockout Cell Lines: What Phenotypes to Expect and How to Verify Them

Reading Chromatin Accessibility: From ATAC-seq Peaks to Functional Hypotheses

Histone Modification Writers, Readers and Erasers: A Knockout Map

Assessing Off-Target Effects in Epigenetic Editing

Single-Cell Epigenomics: scATAC-seq and scChIP-seq in Development and Disease

Spatial Epigenomics: Mapping Modifications In Situ

Epigenetic Clocks and cfDNA Methylation as Biomarkers

Imprinting and Parent-of-Origin Expression: Why Allele-Specific Regulation Matters

What Is CRISPRoff and How Does It Differ From dCas9-KRAB?

How Stable Is Epigenetic Silencing Across Cell Divisions?

Which Cell Line Is Best for Studying DNA Methylation?

How to Validate a DNMT1 Knockout Clone

What Is a Differentially Methylated Region (DMR)?

Do Epigenetic Edits Create Off-Target Methylation Changes?

How to Link ATAC-seq Changes to Gene Expression Causality

What Is Histone Lactylation and Why Does It Matter?

How to Design a Single-Cell ATAC-seq Experiment

Can Epigenetic Editing Restore a Silenced Gene?

lncRNA, miRNA and RNA Modification: A Complete Path from Function Prediction to Phenotype Validation

Why lncRNA Knockouts Often Show No Phenotype — and How to Design Around It

lncRNA Functional Validation: Knockout vs Knockdown vs Antisense Oligonucleotides

m6A Writers, Readers and Erasers: Mapping and Testing RNA Modification Function

miRNA–Target Validation: Evidence Beyond Luciferase Reporter Assays

RNA-Binding Protein Screens: Design, Readouts and Hit Prioritization

Alternative Splicing Regulation: Isoform-Level Validation Strategies

Circular RNA Biology: Detection, Function and Experimental Pitfalls

RNA Localization and the Spatial Regulation of Translation

Why Does an lncRNA Knockout Often Show No Phenotype?

Knockdown vs Knockout for lncRNA: Which Is More Informative?

How Long a Fragment Should Be Deleted for an lncRNA Knockout?

Which m6A Antibody Should I Use for MeRIP-seq?

What Is the Difference Between RIP-seq and CLIP-seq?

How to Validate a miRNA Target Without a Luciferase Assay

How Many Isoforms Must an Alternative Splicing Study Cover?

Is Circular RNA Detection Reliable Across Platforms?

How to Verify RNA Localization Experimentally

What Proportion of Annotated lncRNAs Are Functional?

CRISPR Knockout, Knock-In, Activation and Screening: A Strategy Matrix for Regulatory Research

Knockout, CRISPRi or Base Editing? A Six-Dimension Decision Matrix

Genome-Wide CRISPR Screening: Library Coverage, MOI and Readout Design

Perturb-seq and Single-Cell Screens: Linking Perturbation to Transcriptional Programs

Essential Genes and Lethal Phenotypes: How to Study What You Cannot Knock Out

Base Editing and Prime Editing in Regulatory Research: When Precision Beats Deletion

Quantifying Editing Efficiency and Off-Target Events: A Practical Framework

Choosing a Cas9 Variant and Delivery Format for Your Cell Type

Multiplex Editing and Temporal Control of Gene Regulation

How Much Library Coverage Is Enough for a Genome-Wide Screen?

What MOI Should I Use for a Lentiviral CRISPR Library?

How to Screen a Non-Proliferative Phenotype

How to Study an Essential Gene with CRISPR

What Is the Difference Between Base Editing and Prime Editing?

How to Measure Knockout Efficiency in a Cell Pool

How to Design a Multiplex Knockout Experiment

Which Cas9 Variant Works Best for AAV Delivery?

What Is a Safe-Harbor Locus for Knock-In?

How Many Clones Must Be Screened to Confirm a Homozygous Knockout?

From Pathway to Model: Validation Paradigms in Cancer, Neuro, Immune and Metabolic Research

Oncogene Dependency and Synthetic Lethality: Building the Right Validation Model

Enhancer Dysregulation in Neurodegeneration: Lessons from Glial and Neuronal Models

CAR-T and ADCC Target Validation: Engineering Immune Cell Lines for Functional Assays

Hippo, WNT and PI3K: Validating Pathway Nodes with Knockout Cell Lines

Drug Target Validation: A Standardized Workflow from Hit to Model

Metabolic Pathway Enzymes: Building Loss-of-Function Models

Gene Editing in iPSC and Organoids: Constraints, Timelines and Readouts

Disease-Associated Non-Coding Variants: From Risk Locus to Cellular Phenotype

How to Validate Pathway Activation After a Knockout

How Long Does iPSC Gene Editing Take?

How to Edit Organoids Without Disrupting Their Structure

Which Cell Line Models ADCC Most Reliably?

How to Build a Synthetic Lethality Screen

What Is a Good Model for Enhancer Dysregulation in Neurons?

How to Validate a Drug Target Before Committing to a Programme

Why Does My Knockout Cell Line Lose the Phenotype After Passaging?

How to Choose Between Human and Mouse Cell Models

What QC Documentation Should Accompany a Custom Cell Line?

Gene Knockout Feasibility Self-Assessment: Ten Constraints That Decide the Project

Pathway-to-Model Reference Chart: Key Genes × Recommended Cell Models

Working with Hard-to-Transfect Cells: A Delivery Strategy Guide

How We Validate Knockout Clones: PCR, Sanger and Western Blot in Combination

Custom Knockout Cell Line Service: Strategy Design, Single-Cell Cloning and Triple Validation

Stable dCas9-KRAB and Cas9 Expression Cell Lines

Knock-In Reporter Cell Lines for Regulatory Readouts

Genome-Wide CRISPR Library Screening Service

Services Comparison: In-House vs CRO vs Off-the-Shelf Cell Lines

Epigenetic Editing Enters the Clinic: What It Means for Research Models

AI Sequence Models in Regulatory Genomics: Hype, Reality and Where They Help

Live-Cell Imaging Rewrites the Rules of Transcriptional Regulation

Spatial and Single-Cell Multi-Omics: The Next Validation Frontier

From CRISPR Screens to Programmable Medicine: A Five-Year Outlook

Contact Us
*
*
*
How did you hear about us: